当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析 - 现金流量表

恒瑞医药

(600276)

  

流通市值:3473.37亿  总市值:3473.37亿
流通股本:63.79亿   总股本:63.79亿

现金流量表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金6,090,507,617.7627,146,811,001.2520,000,144,131.4613,505,722,033.49
收到其他与经营活动有关的现金211,428,920.531,322,070,742.88546,652,931.24332,597,535.78
经营活动现金流入的平衡项目0000
经营活动现金流入小计6,301,936,538.2928,468,881,744.1320,546,797,062.713,838,319,569.27
购买商品、接受劳务支付的现金347,352,720.651,402,150,450.751,130,472,262.16784,683,468.64
支付给职工以及为职工支付的现金1,905,586,260.316,163,445,682.384,610,758,220.713,100,793,377.51
支付的各项税费652,139,252.42,290,150,446.161,652,291,637.651,256,569,717.17
支付其他与经营活动有关的现金2,841,684,216.4211,190,382,126.138,567,828,933.065,663,518,164.77
经营活动现金流出的平衡项目0000
经营活动现金流出小计5,746,762,449.7821,046,128,705.4215,961,351,053.5810,805,564,728.09
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额555,174,088.517,422,753,038.714,585,446,009.123,032,754,841.18
二、投资活动产生的现金流量:
收回投资收到的现金150,000,000605,485,304.68200,000,000-
取得投资收益收到的现金18,785,809.652,505,139.4543,037,372.9535,223,637.55
处置固定资产、无形资产和其他长期资产收回的现金净额1,568,511.6121,901,7398,183,649.55,857,667.51
投资活动现金流入的平衡项目0000
投资活动现金流入小计170,354,321.21679,892,183.13251,221,022.4541,081,305.06
购建固定资产、无形资产和其他长期资产支付的现金702,031,901.521,969,197,487.861,524,667,512.24964,673,726.04
投资支付的现金-622,680,411.5600,000,000600,000,000
投资活动现金流出的平衡项目0000
投资活动现金流出小计702,031,901.522,591,877,899.362,124,667,512.241,564,673,726.04
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-531,677,580.31-1,911,985,716.23-1,873,446,489.79-1,523,592,420.98
三、筹资活动产生的现金流量:
取得借款收到的现金-799,909,380.08799,909,380.08799,909,380.08
筹资活动现金流入平衡项目-000
筹资活动现金流入小计-799,909,380.08799,909,380.08799,909,380.08
偿还债务支付的现金-799,909,380.08799,909,380.08799,909,380.08
分配股利、利润或偿付利息支付的现金-1,274,788,274.051,274,788,274.051,019,953.25
支付其他与筹资活动有关的现金661,059,213.92275,801,751.83231,735,776.01137,547,567.63
筹资活动现金流出平衡项目0000
筹资活动现金流出小计661,059,213.922,350,499,405.962,306,433,430.14938,476,900.96
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-661,059,213.92-1,550,590,025.88-1,506,524,050.06-138,567,520.88
四、汇率变动对现金及现金等价物的影响29,624,153.667,400,551.34-21,219,513.59-5,838,450.66
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-607,938,552.063,967,577,847.941,184,255,955.681,364,756,448.66
加:期初现金及现金等价物余额24,239,102,117.6620,271,524,269.7220,271,524,269.7220,271,524,269.72
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额23,631,163,565.624,239,102,117.6621,455,780,225.421,636,280,718.38
补充资料:
净利润-6,336,994,647.53-3,428,132,358.04
资产减值准备-32,538,341.38--15,816,450.54
固定资产和投资性房地产折旧-655,021,624.88-313,708,012.88
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-655,021,624.88-313,708,012.88
无形资产摊销-67,263,980.25-28,223,961.4
长期待摊费用摊销-94,789,854.75-49,076,304.56
处置固定资产、无形资产和其他长期资产的损失--5,397,912.01--2,015,408.01
固定资产报废损失-4,944,029.96-1,868,321.58
公允价值变动损失--108,630,771.57--7,542,196.34
财务费用--1,841,800.26--11,929,279.97
投资损失--23,868,290.32-6,007,841.47
递延所得税--23,141,400.15--82,332,187.42
其中:递延所得税资产减少--56,618,467.73--83,786,038.15
递延所得税负债增加-33,477,067.58-1,453,850.73
存货的减少--135,630,816.98-77,839,354.29
经营性应收项目的减少--375,699,363.85--2,548,575,946.35
经营性应付项目的增加-671,408,644.5-1,614,929,285.73
其他-209,255,274.64-109,865,787.99
现金的期末余额-24,239,102,117.66-21,636,280,718.38
减:现金的期初余额-20,271,524,269.72-20,271,524,269.72
公告日期2025-04-252025-03-312024-10-252024-08-22
审计意见(境内)标准无保留意见
TOP↑